Nomura Holdings’s Apellis Pharmaceuticals APLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.41M Sell
59,800
-50,300
-46% -$1.08M 0.01% 875
2025
Q4
$2.77M Sell
110,100
-6,400
-5% -$150K ﹤0.01% 981
2025
Q3
$2.64M Buy
+116,500
New +$2.72M ﹤0.01% 1036
2024
Q1
Sell
-12,400
Closed -$742K 1603
2023
Q4
$742K Buy
+12,400
New +$629K ﹤0.01% 1261
2023
Q3
Sell
-97,200
Closed -$8.85M 1365
2023
Q2
$8.85M Buy
+97,200
New +$8.39M 0.02% 367

Other funds holding APLS

Nomura Holdings's APLS Position: Q1 2026 in Review

Nomura Holdings sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 14,200 shares — an estimated $306K sold.

Nomura Holdings first reported a position in APLS in Q3 2019 and held it in 16 quarters. The position peaked at $9.56M in Q3 2021. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Nomura Holdings reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Nomura Holdings sold 14,200 Apellis Pharmaceuticals shares in Q1 2026, an estimated $306K.
  • Nomura Holdings first reported a position in Apellis Pharmaceuticals in Q3 2019 and held it in 16 quarters.
  • Nomura Holdings's Apellis Pharmaceuticals position peaked at $9.56M in Q3 2021.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.